SCHEMBL969019

SCHEMBL969019

O=C(CN1CCc2c([nH]c3ncc(-c4cncnc4)cc23)C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.46
HRH3 Q9Y5N1 2/20 0.40
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
PRMT5 O14744 3/20 0.34
WDR77 Q9BQA1 3/20 0.34
CDK9 P50750 3/20 0.34
CCNT1 O60563 2/20 0.34
CDK2 P24941 2/20 0.34
CCNA2 P20248 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
CHEK1 O14757 1/20 0.33
ACHE P22303 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CDK1 P06493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968696 0.87 PARP1 (0.50) PARP1HRH3PDE3BPDE3AKDM4E
SCHEMBL967686 0.87 PARP1 (0.43) PARP1HRH3PDE3BPDE3AKDM4E
SCHEMBL971431 0.87 PARP1 (0.49) PARP1HRH3KDM4EALDH1A1HPGD
SCHEMBL968632 0.86 PARP1 (0.48) PARP1HRH3KDM4EALDH1A1HPGD
SCHEMBL13985903 0.86 PARP1 (0.49) PARP1HRH3PDE3BPDE3AKDM4E
SCHEMBL967359 0.85 PARP1 (0.47) PARP1HRH3CDK9CDK7IRAK4
SCHEMBL967934 0.84 PARP1 (0.48) PARP1HRH3KDM4EALDH1A1HPGD
SCHEMBL967354 0.83 PARP1 (0.47) PARP1HRH3PDE3BPDE3AKDM4E
SCHEMBL970423 0.80 PARP1 (0.57) PARP1HRH3KDM4EALDH1A1HPGD
SCHEMBL968881 0.79 PARP1 (0.46) PARP1HRH3PDE3BPDE3AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885HRH3 1/4885PDE3B 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.